CD274 and neoplasm: M7824 (bintrafusp alfa; Strauss et al, 2018), composed of TGF‐βRII fused to a PD‐L1 antibody to target TGF‐β in tumor microenvironment (TME) and PD‐L1 for local immune modulation, unfortunately failed to improve overall survival (OS) and PFS in a phase 3 clinical trial (NCT03631706) in NSCLC compared with pembrolizumab.